Janssen’s BCMA-Targeting CAR-T, AstraZeneca’s Evusheld Among EU Verdict Hopefuls
The EMA is poised to say whether or not six new drugs are on track for pan-EU approval, including Janssen’s first cell therapy and an antibody combination to prevent COVID-19 in people with poor immune response.
You may also be interested in...
The European Medicines Agency’s human medicines committee has recommended five new drugs for use in the EU at its latest monthly meeting.
The European Medicines Agency was this week deciding whether to grant accelerated assessment for glofitamab.
The European Commission is expected to make a “rapid decision” on the European Medicines Agency’s recommendation today that Evusheld should be approved.